Company profilePharmaceutical#1224 of 1,318 in Pakistan✓ No DRAP alerts

Titlis Pharma (Private) Limited DSL: 05-352-0066-035681D

Pharmaceutical company · 1 brands · 6 molecules

Ranked #10 of 10 companies in Other Antianemic Preparations (Erythropoietin Products)

1 registered products 6 pharmaceutical brands 6 distinct molecules 0 DRAP alerts

Company overview

1
registered products
6
pharmaceutical brands
6
distinct molecules
1
therapeutic classes
0
DRAP alerts

Titlis Pharma (Private) Limited DSL: 05-352-0066-035681D is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 1 product registration across 6 distinct molecules. Its portfolio is concentrated in Other Antianemic Preparations (Erythropoietin Products). It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Top molecules by brand count

Recombinant Human Erythropoietin ...... 5000 Iu1 brand
Recombinant Human Erythropoietin ...... 4000 Iu1 brand
Epoetin1 brand
Recombinant Human Erythropoietin ...... 2000 Iu1 brand
Recombinant Human Erythropoietin ...... 3000 Iu1 brand

Therapeutic classes

Other Antianemic Preparations (Erythropoietin Products) · 1

Price band (DRAP official ceilings)

Registered products priced by source
DRAP-official7 products · Rs 2,090.69 – Rs 18,222.28
Median across source: Rs 3,158.18

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

Medipak (Pvt) Ltd4 shared molecules
RG PHARMA4 shared molecules
SEARLE PAKISTAN (PVT.) LTD.2 shared molecules
GENE-TECH LABORATORIES2 shared molecules
Aspin Pharma (Pvt) Ltd2 shared molecules

Get the full profile for Titlis

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.